Tyrosine Kinase Inhibitor Emodin Suppresses Growth of HER-2/neu-overexpressing Breast Cancer Cells in Athymic Mice and Sensitizes These Cells to the Inhibitory Effect of Paclitaxel
作者： Gabriel N. Hortobagyi , Mien Chie Hung , Weiya Xia , Lisha Zhang , Yiu Keung Lau
DOI:
关键词: Biology 、 Emodin 、 Tyrosine kinase 、 Receptor tyrosine kinase 、 Tyrosine phosphorylation 、 Endocrinology 、 Cancer cell 、 Tyrosine-kinase inhibitor 、 Internal medicine 、 Cancer research 、 Cell growth 、 Tyrosine
摘要: Overexpression of the HER-2/neu proto-oncogene, which encodes tyrosine kinase receptor p185neu, has been observed in tumors from breast cancer patients. We demonstrated previously that emodin, a inhibitor, suppresses activity HER-2/neu-overexpressing cells and preferentially represses transformation phenotypes these vitro. In present study, we examined whether emodin can inhibit growth mice sensitize to paclitaxel, commonly used chemotherapeutic agent for found significantly inhibited tumor prolonged survival bearing human cells. Furthermore, combination paclitaxel synergistically anchorage-dependent -independent vitro athymic s.c. xenografts expressing high levels p185neu. Both immunohistochemical staining Western blot analysis showed decreases phosphorylation tissue. Taken together, our results suggest is required chemoresistance inhibitors such as also paclitaxel. The may have important implications chemotherapy tumors.
aacrjournals.org参考文章(68)
Drebin Ja, Link Vc, Greene Mi, Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene. ,vol. 2, pp. 273- ,(1988)
Toyoshima K, Sakamoto H, Nomura N, Yamamoto T, Terada M, Yoshida T, Yokota J, Sugimura T, Miyajima N, Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene. ,vol. 2, pp. 283- 287 ,(1988)
A D Seidman, L Norton, J Baselga, P P Rosen, HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology. ,vol. 11, pp. 43- 48 ,(1997)
Ming Tan, Mien Chie Hung, Dihua Yu, Bolin Liu, Shan Shue Wang, Junzhi Li, Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene. ,vol. 13, pp. 1359- 1365 ,(1996)
M D Pegram, R J Pietras, S B Howell, V R Chazin, B M Fendly, D J Slamon, Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. ,vol. 9, pp. 1829- 1838 ,(1994)
Jay R. Harris, Marc E. Lippman, Umberto Veronesi, Walter Willett, Breast cancer: (Second of three parts) The New England Journal of Medicine. ,vol. 327, pp. 390- 398 ,(1992) , 10.1056/NEJM199208063270606
D. Gershenson, M. C. Hung, X. Zhang, E. Silva, Amplification and rearrangement of c-erb B proto-oncogenes in cancer of human female genital tract. Oncogene. ,vol. 4, pp. 985- 989 ,(1989)
John Leyden. Webb, Enzyme and metabolic inhibitors Academic Press. ,(1963) , 10.5962/BHL.TITLE.7320
Peter C. Nowell, Adi Gazdar, William V. Williams, David B. Weiner, Robert Robinson, Mark I. Greene, Jeffrey A. Cohen, Joanne Nordberg, Jeffrey A. Kern, Jeffrey A. Kern, Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung Cancer Research. ,vol. 50, pp. 421- 425 ,(1990)
Angela R. Winnier, Angela R. Winnier, Carlos L. Arteaga, Stephen D. Hurd, Stanford J. Stewart, Laura K. Shawver, Miriam C. Poirier, Daniel M. Lopez-Larraza, p185c-erbB-2 signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells : association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair Cancer Research. ,vol. 54, pp. 3758- 3765 ,(1994)